Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552172 | 0.93 | ALOX5 (0.46) | ALOX5CES1GPR84PDK2 | |
| SCHEMBL2378791 | 0.92 | GPR84 (0.40) | ALOX5CES1GPR84TSHRMAPK1 | |
| SCHEMBL2380542 | 0.91 | GPR84 (0.39) | ALOX5CES1GPR84PDK2HPGD | |
| SCHEMBL29702907 | 0.90 | ALOX5 (0.42) | ALOX5CES1PDK2 | |
| SCHEMBL2381883 | 0.90 | ALOX5 (0.39) | ALOX5CES1GPR84ALDH1A1HPGD | |
| SCHEMBL27867338 | 0.89 | ALOX5 (0.41) | ALOX5CES1PDK2 | |
| SCHEMBL2381317 | 0.88 | ALOX5 (0.35) | ALOX5CES1GPR84PDK2ALDH1A1 | |
| SCHEMBL2397945 | 0.88 | ALOX5 (0.35) | ALOX5CES1GPR84PDK2ALDH1A1 | |
| SCHEMBL19569658 | 0.87 | ALOX5 (0.44) | ALOX5CES1GPR84MAPK1L3MBTL1 | |
| SCHEMBL12186014 | 0.86 | PDK2 (0.40) | ALOX5PDK2ALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8525158-B2 | Anthracene derivative and organic electroluminescence element using the same | DOOSAN CORPORATION (KR) | 2013-09-03 | — | — | US | disclosed |
| US-20110210320-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME | DOOSAN CORPORATION (KR) | 2011-09-01 | — | — | US | disclosed |
| WO-2010027181-A2 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME | 주식회사 두산 (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110210320-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME | KCNJ2, KCNJ1, BRD4 | ALOX5 1930/4885CES1 4481/4885GPR84 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.